Impact of the UK COVID‐19 pandemic on HbA1c testing and its implications for diabetes diagnosis and management
Published Date: 19th March 2021
Publication Authors: Green L
Extract
Letter to the Editor
Diabetes mellitus (DM) is a risk factor for poor outcome in patients with COVID‐19.1 However, the focus on mitigating the effects of SARS‐CoV‐2 has resulted in many routine healthcare services, including blood test monitoring in conditions such as DM, being disrupted.
We recently explored the impact of the COVID‐19 pandemic on DM diagnosis and management using routinely collected laboratory data on the key DM test, glycated haemoglobin (HbA1c).
Holland, D; Green, L et al . (2021). Impact of the UK COVID‐19 pandemic on HbA1c testing and its implications for diabetes diagnosis and management. International Journal of Clinical Practice. 75 (4), e13980